Press Releases

Mar 29, 2026

Hana Yamamoto

Press Releases

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Sight Sciences announced that the U.S. District Court for the District of Delaware upheld a jury verdict finding Alcon willfully infringed three of Sight Sciences' patents related to glaucoma treatment devices. The Court awarded Sight Sciences $34 million in past damages plus supplemental damages and interest, and granted an ongoing 10% royalty on …

SGHT

Mar 29, 2026

Derek Hwang

Press Releases

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

PMGC Holdings Inc. (NASDAQ: ELAB) filed its 2025 Annual Report highlighting a 43% growth in total assets to $12.87 million, driven by three strategic acquisitions in precision manufacturing and specialty IT hardware packaging serving aerospace, defense, and semiconductor sectors. The company also advanced its biopharmaceutical subsidiary, Northstri…

ELAB

Mar 29, 2026

Caleb Monroe

Press Releases

Connect Biopharma Announces $20.2 Million Private Placement Financing

Connect Biopharma announced a $20.2 million private placement financing led by existing investor Panacea Venture, extending its cash runway through the second half of 2027. The funds will support the development of its clinical-stage drug candidates targeting inflammatory diseases such as asthma and COPD, particularly the next-generation antibody r…

CNTB

Mar 29, 2026

Priya Menon

Press Releases

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Connect Biopharma announced promising Phase 3 clinical trial results of its drug rademikibart for moderate-to-severe atopic dermatitis. The 52-week study demonstrated rapid, durable efficacy with a high percentage of patients achieving significant skin clearance and an excellent safety profile comparable to placebo. The data were presented at the 2…

CNTB

Mar 29, 2026

Leila Farooq

Press Releases

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics announced successful completion of a Type A meeting with the FDA regarding the resubmission of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film, reaffirming plans to resubmit in Q3 2026. The FDA provided clarifying feedback on pharmacokinetic and human factor study designs, and the company is pre…

AQST

Mar 29, 2026

Marcus Reed

Press Releases

Smart Share Global Limited Granted Exception by Nasdaq Staff Related to Filing of Its Interim Report

Smart Share Global Limited, a Nasdaq-listed consumer tech company providing mobile device charging services in China, has been granted an exception by Nasdaq staff regarding the late filing of its interim financial report for the half-year ended June 30, 2025. The company must file the report by June 29, 2026 to maintain compliance with Nasdaq list…

EM

Mar 29, 2026

Marcus Reed

Press Releases

Terrestrial Energy Announces Fourth Quarter and Full Year 2025 Results

Terrestrial Energy announced its Q4 and full year 2025 results highlighting selection by Texas A&M for commercial IMSR plant deployment, NRC acceptance of principal design criteria, DOE awards for reactor and fuel pilot projects, and a successful business combination raising $292 million. The company strengthened its position in the US energy marke…

IMSR

Mar 29, 2026

Maya Rios

Press Releases

Digital Realty Announces Final Close of $3.25 billion U.S. Hyperscale Data Center Fund

Digital Realty announced the final close of its first U.S. hyperscale data center fund, securing $3.25 billion from institutional investors to own and develop major hyperscale data centers across key U.S. metro areas. The company will manage the fund with a 20% stake and has added two senior executives to strengthen its private capital platform, ai…

DLR

Mar 29, 2026

Nina Shah

Press Releases

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

PDS Biotechnology Corporation reported financial results for 2025 and updated on clinical progress, including a Phase 3 trial amendment for PDS0101 that incorporates progression-free survival as an interim primary endpoint, potentially shortening trial duration and costs while preserving overall survival as the full approval endpoint. Early promisi…

PDSB

Mar 29, 2026

Nina Shah

Press Releases

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

Connect Biopharma announced positive topline results from its Phase 1 clinical study of intravenous rademikibart, a next-generation anti-IL-4Rα antibody, demonstrating rapid and sustained lung function improvements in asthma and COPD patients. The drug produced clinically meaningful FEV1 increases as early as 15 minutes after dosing and was well to…

CNTB

Mar 29, 2026

Hana Yamamoto

Press Releases

Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries

Seer, Inc. announced that the U.S. Patent and Trademark Office's Patent Trial and Appeal Board upheld 23 claims of its crucial patent for nano- and microparticle protein enrichment technology used in its Proteograph platform. The decision affirms the intellectual property strength of Seer's proprietary proteomic analysis methods, securing its compe…

SEER

Mar 29, 2026

Avery Klein

Press Releases

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences reported strong financial results for Q4 and full year 2025, highlighted by accelerated enrollment in its global Phase 3 CoMpass trial for early choroidal melanoma with enrollment completion expected mid-2026 and topline data anticipated in the second half of 2027. The company is also progressing clinical trials in bladder cancer (…

AURA

Mar 29, 2026

Jordan Park

Press Releases

Bitfarms to Participate in Jefferies Fireside Chat

Bitfarms Ltd., a North American digital infrastructure and energy company specializing in data centers and energy infrastructure for high-performance computing including AI workloads, will participate in a Jefferies Virtual Power x Data Center Conference fireside chat featuring CEO Ben Gagnon and CFO Jonathan Mir.

BITF

Mar 29, 2026

Derek Hwang

Press Releases

BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for BBP-418, a potential first and only treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The submission includes positive interim Phase 3 FORTIFY trial data demonstrating significant improvements in ambulation and pulmonary function, and a favorable safety pr…

BBIO

Mar 29, 2026

Derek Hwang

Press Releases

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Inc., a clinical-stage biopharmaceutical company, announced a poster presentation at the 2026 AACR Annual Meeting showcasing data on the combination of Plinabulin with antibody-drug conjugates and immune checkpoint inhibitors, highlighting enhanced antitumor efficacy. This presentation underscores Plinabulin's potential in cancer immun…

BYSI

Mar 29, 2026

Nina Shah

Press Releases

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma announced key opinion leader validation of its Phase 2 SkinJect clinical data demonstrating an approximately 80% overall response rate in treating nodular basal cell carcinoma. The data supports continued clinical development with a focus on a 200µg dose regimen and highlights SkinJect's potential as a non-surgical treatment alternat…

MDCX

Mar 29, 2026

Derek Hwang

Press Releases

BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

BullFrog AI Holdings has entered a commercial agreement with a top 5 global pharmaceutical company to apply its AI-driven bfLEAP® platform to identify and prioritize novel drug targets for major depressive disorder (MDD). This collaboration aims to accelerate the customer's drug discovery and clinical development programs for MDD, a market valued a…

BFRG

Mar 29, 2026

Hana Yamamoto

Press Releases

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Palvella Therapeutics announced a scientific publication in the Journal of Vascular Anomalies outlining the unique challenges of treating microcystic lymphatic malformations (LMs) and emphasizing the unmet medical need. The review underscores clinical distinctions between microcystic and macrocystic LMs and supports Palvella's QTORIN™ 3.9% rapamyci…

PVLA

Mar 29, 2026

Ajmal Hussain

Press Releases

Red Cat Closes Acquisition of Apium Swarm Robotics

Red Cat Holdings, Inc., a U.S.-based provider of advanced multi-domain drone and robotic solutions for defense and national security, has acquired Apium Swarm Robotics. This acquisition enhances Red Cat's ability to deliver intelligent, coordinated swarming autonomy for drones and uncrewed surface vessels, supporting operations in contested and com…

RCAT

Mar 29, 2026

Nina Shah

Press Releases

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Bicara Therapeutics reported strong fourth quarter and full year 2025 financial results alongside significant clinical progress including the initiation of Phase 3 for their lead drug candidate ficerafusp alfa in HPV-negative head and neck cancer. The company confirmed 1500mg as the optimal weekly dose, is advancing less frequent dosing schedules, …

BCAX

Mar 29, 2026

Derek Hwang

Press Releases

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen announced FDA approval of a high dose regimen of SPINRAZA (nusinersen) for treating spinal muscular atrophy (SMA). The approval is based on the pivotal DEVOTE study that demonstrated significant motor function improvements in infants with SMA and a safety profile consistent with the established low dose regimen. The new regimen offers higher…

BIIB

Mar 29, 2026

Ajmal Hussain

Press Releases

Asure Appoints Tiffany Mortimer as Chief Transformation & People Officer

Asure Software appointed Tiffany Mortimer as Chief Transformation & People Officer to lead its operational and organizational transformation initiatives, aligning with the company's focus on advancing AsureCentral and AI-enhanced human capital management solutions. Mortimer's extensive experience in SaaS operational leadership and transformation is…

ASUR

Mar 29, 2026

Maya Rios

Press Releases

Anavex Life Sciences Provides Comprehensive Regulatory Update

Anavex Life Sciences Corp. provides a regulatory update on its lead drug candidate blarcamesine, highlighting ongoing discussions with the European Medicines Agency (EMA) for early Alzheimer’s disease following the withdrawal of EU marketing authorization application. Additional data has been submitted to the U.S. FDA to explore pathways toward a N…

AVXL

Mar 29, 2026

Avery Klein

Press Releases

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

Alterity Therapeutics announced positive regulatory feedback from a Type C Meeting with the FDA regarding its planned Phase 3 clinical trial program for ATH434 targeting Multiple System Atrophy (MSA). The FDA has provided written support for clinical pharmacology and non-clinical development plans, marking a significant step toward initiating the P…

Mar 29, 2026

Avery Klein

Press Releases

Virtuix Signs Cooperative Research and Development Agreement with U.S. Navy

Virtuix Inc. signed a Cooperative Research and Development Agreement with the Naval Postgraduate School to evaluate its Omni One virtual reality system for military training and simulation. This marks Virtuix's first formal research collaboration with the U.S. Navy and builds on existing partnerships with other military branches. The technology ena…

VTIX